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The marine natural product symplostatin 4 (Sym4)
has been recognized as a potent antimalarial agent.
However, its mode of action and, in particular, direct
targets have to date remained elusive. We report
a chemical synthesis of Sym4 and show that Sym4-
treatment of P. falciparum-infected red blood cells
(RBCs) results in the generation of a swollen food
vacuole phenotype and a reduction of parasitemia
at nanomolar concentrations. We furthermore dem-
onstrate that Sym4 is a nanomolar inhibitor of
the P. falciparum falcipains in infected RBCs, sug-
gesting inhibition of the hemoglobin degradation
pathway as Sym4’s mode of action. Finally, we
reveal a critical influence of the unusual methyl-
methoxypyrrolinone (mmp) group of Sym4 for potent
inhibition, indicating that Sym4 derivatives with
such a mmp moiety might represent viable lead
structures for the development of antimalarial falci-
pain inhibitors.
INTRODUCTION
Malaria is a devastating disease that affects approximately
215 million patients annually, among whom around 650,000
die (WHO, 2011). The spread of the disease can normally be
controlled by a combination of vector control and chemo-
therapy. However, there is widespread resistance of the malaria
parasite to most front-line therapeutics. In recent years, an
emergence of resistance against artemisinin-based combination
therapy, which is the standard of care recommended by the
WHO for uncomplicated malaria, has furthermore been noted
in Southeast Asia (Dondorp et al., 2009). Consequently, alterna-
tive chemotherapeutic strategies for combating malaria are
required at a constantly increasing rate (Guiguemde et al.,
2012; Wells et al., 2009).1546 Chemistry & Biology 19, 1546–1555, December 21, 2012 ª2012Due to an impressive structural diversity in combination with
often potent bioactivities, natural products have proven to
be valuable lead structures for drug discovery (Mayer et al.,
2010). Their further development into drugs is, however, often
hampered by a lack of knowledge of their mode of action.
Consequently, several strategies for the identification of the
direct targets of bioactive natural products have been developed
in the past few years (Lomenick et al., 2011; Rix and Superti-
Furga, 2009). Among them, proteome labeling strategies such
as activity-based protein profiling (ABPP) have evolved into
reliable tools for the identification of protein targets of potentially
bioreactive natural small molecules (Bo¨ttcher et al., 2010;
Cravatt et al., 2008; Deu et al., 2012; Heal et al., 2011; van der
Hoorn et al., 2004).
In 2009, the cyanobacterial secondarymetabolites symplosta-
tin 4 (Sym4, Figure 1A) and gallinamide A were independently
isolated from the species Symploca sp. and Schizothrix sp.,
respectively (Linington et al., 2009; Taori et al., 2009).
Subsequent total syntheses of these two natural products and
structural characterizations revealed that both compounds are
in fact identical (Conroy et al., 2010, 2011). Subsequent biolog-
ical evaluations of Sym4 demonstrated their potent antimalarial
properties: In fact, gallinamide A (and, therefore, Sym4), as
well as three chemically synthesized diastereomers that differed
only in the stereochemistry of their N-terminal isoleucine residue,
turned out to be potent nanomolar growth inhibitors of the
malaria parasite P. falciparum (strain 3D7 and W2, IC50s of
36–100 nM) (Conroy et al., 2010, 2011; Linington et al., 2009).
Notably, no lysis of red blood cells (RBCs) was observed during
Sym4 treatment even at the highest tested concentrations
(>25 mM) (Conroy et al., 2010), indicating that its antiparasitic
effect is not due to permeabilization of the RBC membrane.
The molecular basis of this antimalarial activity, however, re-
mained elusive.
Sym4 (Figure 1A) thereby displays several structural features
that are only rarely found in natural products. For example,
Sym4 features a (4S)-amino-(2E)-pentenoic acid that is linked
with a methyl-methoxypyrrolinone (mmp) unit at its C-terminal
end and an isocaproic acid moiety involved in an ester bondElsevier Ltd All rights reserved
Figure 1. Structure and Synthesis of Sym4 and Sym4 Derivatives
(A) Molecular structure of the parent natural product symplostatin 4 (Sym4).
(B) Reagents and conditions: (a) 1. NH(OMe)Me*HCl, Et3N, DCC, DCM; 2. LiAlH4, Et2O, (EtO)2P(O) = CHCOOMe, DCM, 59%; (b) 1. LiOH, THF/MeOH/H2O; 2.
HAlaOMe*HCl, HOBt, HBTU, DIPEA, DCM, 46%; (c) 1. LiOH, THF/MeOH/H2O; 2. Meldrum’s acid, EDC, DMAP, DCM; 3. CH3CN, reflux; 4. PPh3, DEAD, MeOH,
THF, 90%; (d) 1. TFA/DCM (1:1); 2. BocLeuOH, HOBt, HBTU, DIPEA, CH3CN, 99% (4), 85% (5); (e) 1. SOCl2, MeOH/DCM; 2. BocNMeIleOH, DCC, DMAP, DCM,
55%; (f) TFA/DCM (1:1); 2. MeI, DIEA, DMF, 38%; (g) TFA/DCM (1:1); 2. Propargyl bromide, DIEA, CH3CN, 63%; (h) 1. LiOH, THF/MeOH/H2O; 2. 4 (after cleavage
with TFA/DCM [1:1]), HBTU, HOBt, DIPEA, CH3CN, 39% (Sym4
mmp/Ala), 53% (hSym4mmp/Ala); (i) 1. LiOH, THF/MeOH/H2O; 2. 5 (after cleavage with TFA/
DCM [1:1]), HBTU, HOBt, DIPEA, CH3CN, 51% (Sym4), 64% (hSym4); (j) RhN3, CuSO4, TBTA, TCEP, H2O, 23% (RhSym4), 67% (RhSym4
mmp/Ala).
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Falcipains as Direct Targets of Symplostatin 4with an N-terminally dimethylated isoleucine residue. The
Michael system in the (4S)-amino-(2E)-pentenoic acid unit is,
thus, potentially bioreactive (Drahl et al., 2005); in fact, covalently
binding cysteine protease inhibitors, proteasome as well as
GAPDH inhibitors, with such Michael acceptor units have been
reported (Clerc et al., 2009a, 2009b; Groll et al., 2008; Kaschani
et al., 2012; Powers et al., 2002). InSym4, this chemical moiety is
uniquely linked to a highly rigid mmp group, which could influ-
ence the bioreactivity and/or target specificity of this natural
product.
The favorable biological activities and intriguing structural
features of Sym4 raise the question of the underlying mode of
action of this antimalarial natural product. To this end, an eluci-
dation of the direct molecular target(s) and of the structural
determinants for bioactivity is highly desirable. Therefore, in
the present study, we chemically synthesized Sym4 and a set
of analogs and characterized their antimalarial properties. In
addition, we identified falcipains as Sym4’s molecular targets
and investigated the role of the mmp group for bioactivity.
RESULTS
Chemical Synthesis of Sym4 and its Derivatives
In order to obtain the required chemical probes for the target
identification studies as well as for the synthesis of Sym4
derivatives lacking the mmp group, we devised a convergent,
fragment-based approach that was used to synthesize Sym4
as well as C- and N-terminally modified Sym4 derivatives (Fig-
ure 1; Supplemental Experimental Procedures available online).
To this end, we retrosynthetically divided Sym4 and the corre-
sponding derivatives into two fragments, i.e., an N-terminal
depsipeptide moiety and a C-terminal tripeptide residue. Such
an approach is beneficial because a ‘‘combinatorial’’ coupling
of differentlymodifiedN- andC-terminal fragments allowsan effi-
cient, cost-effective, and rapid generation of various Sym4
derivatives.
With this plan in mind, we started our synthesis with the
generation of two different C-terminal fragments that varied in
the presence or absence of the mmp group (Figure 1B). Accord-
ingly, Boc-Ala-OH was converted to an a,b-unsaturated methyl
ester 1 in 59% yield using a protocol introduced by Pollini and
coworkers (Benetti et al., 2002). In the next step, ester 1 was
deprotected using lithium hydroxide and coupled with alanine
methyl ester hydrochloride to obtain dipeptide intermediate
2. Dipeptide 2 was deprotected C-terminally with lithium
hydroxide and the resulting intermediate was coupled with
Meldrum’s acid, yielding a highly reactive enol intermediate
that rearranged into a pyrrolidine-2,4-dione moiety upon reflux
in acetonitrile. The use of Mitsunobu conditions (DEAD, meth-
anol, and triphenylphosphine) then transformed this pyrroli-
dine-2,4-dione into the desired mmp-modified dipeptide 3 in
90% yield (Patino et al., 1992). The final C-terminal tripeptide
building block 5 was then obtained in 85% yield by Boc depro-
tection of 3, followed by a coupling step with Boc-Leu-OH and
HBTU/HOBt activation and acetonitrile as the solvent (Jou et al.,
1997). In contrast, the tripeptide building block 4 that lacks
a mmp group but features, instead, an alanine residue was
obtained by acidic Boc deprotection of 2 and subsequent
coupling of the free amine to Boc-Leu-OH, again with1548 Chemistry & Biology 19, 1546–1555, December 21, 2012 ª2012HBTU/HOBt activation and acetonitrile as the solvent (Jou
et al., 1997).
The two different N-terminal depsipeptide fragments—i.e.,
one building block with an N-dimethylated isoleucine residue
(7) and the other one with an N-methyl-propargyl-modified
isoleucine moiety (8)—were synthesized next. To this end,
(S)-2-hydroxy-isocaproic acid was converted into a methyl
ester and coupled with N-methylated Boc-isoleucine, thereby
yielding the desired depsipeptide 6. The Boc group was cleaved
and the resulting intermediate modified at its N-terminal amino
group with either a methyl (7) or a propargyl group (8).
For fragment assembly, the corresponding N- and C-terminal
building blocks were then coupled with each other.
Accordingly, the N-terminal dipeptide fragments 7 and 9 were
first C-terminally deprotected by saponification with lithium
hydroxide and then directly coupled to the Boc-deprotected
C-terminal tripeptide fragments 4 or 5, using HBTU/HOBt
activation. This approach delivered the desired natural product
Sym4 (51%) and the derivatives for structure-activity rela-
tionship studies (i.e., the alkyne-tagged derivative hSym4
[64%] as well as the corresponding Sym4mmp/Ala [39%]
andhSym4mmp/Ala [53%] derivatives without the mmp group).
Finally, the propargyl-modified analogs hSym4 and
hSym4mmp/Ala were tagged with a rhodamine fluorophore,
using a Cu+-mediated Huisgens [3+2] cycloaddition and Rh-N3
(Kolb et al., 2001; Speers et al., 2003). This approach resulted
in the generation of two fluorescent probes RhSym4 and
RhSym4mmp/Ala that were later used in the ABPP experiments.
Biological Assays Reveal the Critical Role of the mmp
Group of Sym4 for Antimalarial Activity
With these compounds in hand, we first evaluated the effect of
Sym4 and Sym4mmp/Ala on malaria parasite replication during
the erythrocytic cycle. To this end, a culture of P. falciparum
D10 parasites at ring stage and 2% parasitemia was treated
for 75 hr (i.e., one and a half life cycles) with different concentra-
tions of Sym4 and Sym4mmp/Ala (Figure 2A). After 75 hr, the
parasites reached schizont stage with completed DNA re-
plication, thereby allowing an efficient differentiation between
infected and noninfected RBCs via propidium iodide staining
and subsequent parasitemia quantification via flow cytometry
as described previously (Deu et al., 2010). Sym4 (EC50 =
0.7 ± 0.2 mM) was 40-fold more potent than Sym4mmp/Ala
(EC50 = 27 ± 7 mM), indicating that the C-terminal mmp group
significantly contributes to the antiparasitic activity of this
compound.
In order to better understand the mechanism of action of
Sym4, we next investigated whether treatment with these
compounds induces a specific phenotype. To this end, ring
stage parasites were treated with different concentrations of
Sym4 and Sym4mmp/Ala. After 24 hr, their morphology was
visualized by Giemsa-stained thin blood smears. In this assay,
cells treatedwith 0.1 mMSym4 already showed a distinct swollen
food vacuole phenotype (Figure 2B, upper panel). On the other
hand, a 100-fold higher concentration of Sym4mmp/Ala was
required to cause the same effect (Figure 2B, lower panel). In
many cases, such a phenotype is caused by accumulation of
nondigested hemoglobin or oligopeptides in the food vacuole,
generally due to inhibition of proteases involved in this pathwayElsevier Ltd All rights reserved
Figure 3. Labeling Pattern of RhSym4 and RhSym4mmp/Ala
Labeling of intact parasites with RhSym4 and RhSym4mmp/Ala. Purified
schizonts were pretreated with 10 mM of the nonfluorescent compounds
Sym4, hSym4, Sym4mmp/Ala, hSym4mmp/Ala, or DMSO. This was fol-
lowed by 1 hr incubation with 10 mM RhSym4 or RhSym4mmp/Ala. The
labeling reaction was stopped by boiling the samples in gel electrophoresis
loading buffer. Proteins were resolved by SDS-PAGE and fluorescent proteins
were visualized with a flatbed fluorescence scanner. The figure was assem-
bled using two regions of the same gel. Lanes irrelevant to the conclusion were
omitted (indicated by white box).
See also Figures S3 and S4.
Figure 2. Comparison of the Biological Activities of Sym4 and
Sym4mmp/Ala
(A)Sym4 inhibits P. falciparum growth at ring stage with an EC50 = 0.7 ± 0.2 mM
and thus at significantly lower concentrations than Sym4mmp/Ala (EC50 = 27 ±
7 mM). Error bars indicate SD from three independent experiments.
(B) Sym4 induces a swollen food vacuole phenotype (indicated by arrows)
at concentrations as low as 0.1 mM, thereby indicating inhibition of the
hemoglobin degradation pathway (Rosenthal, 2004, 2011). Intriguingly,
Sym4mmp/Ala, the Sym4 derivative with alanine instead of the methyl-
methoxypyrrolinone unit, requires concentrations of 10 mM to achieve the
same phenotype.
See also Figure S1.
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defects have been reported in the literature: (1) A red swollen
food vacuole that is observed when proteases involved at the
initial stages of hemoglobin degradation are inhibited (falcipains
2/20/3). This results in an accumulation of undigested hemo-
globin that still contains the heme group (red color). (2) A clear
swollen food vacuole was recently reported due to an inhibition
of aminopeptidases (Harbut et al., 2011), which does not block
the initial breakdown of hemoglobin but results in the accumula-
tion of undigested peptides (clear). In the case of Sym4 treat-
ment, we observed a red food vacuole defect, which indicates
that Sym4 blocks the initial stages of hemoglobin degradation.
We did not observe lysis of RBCs with either of the two
compounds, which is in accordance with previously published
data (Conroy et al., 2010). Finally, a dead phenotype was
observed at 100 mM (Figure 2B). This is most likely due to
a general toxic effect caused by the reactivity of the (4S)-
amino-(2E)-pentenoic acid unit found in this class of compounds.
To determine whether Sym4 had any effect on parasite egress
from infected RBCs or erythrocyte invasion, we then treated
trophozoites for 24 hr with different concentrations of Sym4
and analyzed the parasites morphology by Giemsa-stained
thin blood smears (Figure S1). No effects were observed belowChemistry & Biology 19, 1546–15510 mM. However, at concentration of 10 mM and above an accu-
mulation of mature schizonts was observed (Figure S1). This
effect was not permanent as these parasites were able to egress
and invade RBCs normally if cultured for another 24 hr in the
presence of Sym4 (Figure S1). Therefore, we assume that this
delay in rupture results from an inhibition of the hemoglobin
degradation by Sym4, which is known to slow down parasite
development.
Labeling of Infected Blood Samples with RhSym4
Reveals One Major Target for Sym4
To clarify whether Sym4 covalently modifies its targets, we
compared the labeling patterns of P. falciparum-infected blood
samples treated with RhSym4 and RhSym4mmp/Ala. To this
end, intact schizonts were incubated with the rhodamine-
modified compounds in the presence or absence of their respec-
tive nonfluorescent derivatives. After incubation, proteins were
isolated and resolved by denaturing PAGE, and the fluorescently
labeled proteins were visualized using a flatbed fluorescence
scanner (Figure 3). In the case of RhSym4, two strongly labeled
protein bands in the 28 kDa region became visible. The labeling
event was sensitive to preincubation with the natural product
Sym4, as well as with the closely related analog hSym4,
indicating that the interaction is indeed dependent on the struc-
ture of the compounds and not an artifact caused by the rhoda-
mine group. On the other hand, the same experiment with
RhSym4mmp/Ala revealed only weak labeling in the 28 kDa
region. Importantly, these results correlate well with the different
potency of Sym4 and Sym4mmp/Ala in the parasite assays
(Figures 2A and 2B).5, December 21, 2012 ª2012 Elsevier Ltd All rights reserved 1549
Figure 4. Characterization of Sym4 Specificity Using Activity-Based
Protein Profiling with Cy5-DCG-04
(A) P. falciparum D10 lysates (in 50 mM NaOAc, pH 5) were preincubated for
30 min with different concentrations of Sym4 or Sym4mmp/Ala, followed by
addition of 1 mM Cy5-DCG-04. After 1 hr, the reaction was stopped by adding
SDS-PAGE loading buffer and boiling for 5 min. Proteins were resolved by
SDS-PAGE and visualized by in-gel detection of fluorescence on a flatbed
fluorescence scanner. Sym4 inhibited FP2/20/3 at low nanomolar concentra-
tions and FP1 at concentrations above 1.6 mM. In contrast, Sym4mmp/Alawas
a much weaker FP2/20/3 inhibitor and did not inhibit FP1 at the concentrations
used. DPAP1, dipeptidyl aminopeptidase 1 (Arastu-Kapur et al., 2008;
Greenbaum et al., 2002b).
(B) Sym4 inhibits the falcipains in living parasite. A culture of P. falciparum at
trophozoite stage was treated for 1 hr with different concentrations of Sym4.
Parasite pellets were separated fromRBCs by saponin lysis and residual PLCP
activities were measured by lysing the pellets in acetate buffer containing 1%
NP40 and 1 mMof Cy5-DCG-04. After 1 hr, the reactionwas stopped by adding
SDS-PAGE loading buffer. Proteins were resolved by SDS-PAGE and visual-
ized by in-gel detection of fluorescence on a flatbed fluorescence scanner.
Sym4 inhibited falcipains 1, 2/20, and 3 at high, low, and medium nanomolar
concentrations (IC50
FP1 = 140 ± 23 nM, IC50
FP2/20 = 8.5 ± 1.3 nM, IC50
FP3 = 22 ±
8 nM), respectively. Sym4 did not inhibit DPAP1 at 1 mM.
See also Figures S2–S5.
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Falcipains as Sym4 Targets
The formation of a food vacuole defect by Sym4, the known bio-
reactivity of vinyl amino acid derivatives toward cysteine prote-
ases, and the labeling of proteins at 28 kDa by RhSym4 strongly
suggested that one ormore of the food vacuole’s falcipains (FP2,
FP20, and FP3) (Rosenthal, 2004, 2011) might be targets of
Sym4. These proteases are plasmodial papain-like cysteine
proteases (PLCPs) that are known to migrate at 28 kDa in an
SDS-PAGE and are important for the proper development of
the parasite in the blood stages (Greenbaum et al., 2002b; Pan-
dey et al., 2006). FP1 is the only falcipain outside of the food
vacuole and is believed to play a role in RBC invasion (Green-
baum et al., 2002b). FP2, FP20, and FP3 are involved in the
hemoglobin degradation pathway, which is the main source of
amino acids for the developing parasite (Sijwali and Rosenthal,
2004). Importantly, inhibition of these three proteases causes
the same phenotype as the one observed for Sym4 treatment
(i.e., a swollen food vacuole and block of parasite replication;
Figure 2) (Moura et al., 2009; Rosenthal et al., 1988). The pheno-
type observed with Sym4 is also reminiscent of the initial
phenotype reported for the P. falciparum FP2 knockout strain.
Parasites lacking FP2 undergo a transient food vacuole swelling
at trophozoite stage that resolves in the schizont stage due to
concomitant expression of FP3 (Sijwali and Rosenthal, 2004;
Sijwali et al., 2006).
In order to probe if Sym4 targets falcipains 2, 20, and 3, we
performed competitive ABPP experiments with the activity-
based PLCP probe Cy5-DCG-04 (Greenbaum et al., 2000). In
competitive ABPP experiments, biological samples are first pre-
incubated with the small-molecule inhibitors of interest, followed
by visualization of residual enzyme activity by a fluorescent
probe (Clerc et al., 2011; Cravatt et al., 2008; Fonovic and
Bogyo, 2008; Jeffery and Bogyo, 2003). In general, such an
approach allows the evaluation of inhibitory potency and speci-
ficity under physiologically relevant conditions.
To this end, parasite lysates were incubated first with different
concentrations of Sym4 or Sym4mmp/Ala and then labeled with
Cy5-DCG-04. Subsequently, proteins were separated by elec-
trophoresis and visualized by in-gel fluorescence detection (Fig-
ure 4A). The advantage of using Cy5-DCG-04 is that its targets in
P. falciparum-infected RBCs have already been identified in
previous studies (Greenbaum et al., 2002a, 2002b; Pandey
et al., 2006). Therefore, a reduction in the intensity of one of
the known signals reveals this PLCP as a target of the tested
compounds. Satisfyingly, Sym4 was found to be an astonish-
ingly potent inhibitor of FP2, FP20, and FP3, inhibiting these
proteases at low nanomolar concentrations (1.5 nM). FP1 was
also inhibited, but at significantly higher concentrations
(>1.6 mM). In contrast, Sym4mmp/Ala proved to be much less
potent, inhibiting Cy5-DCG-04 labeling of FP2, FP20, and FP3
only at concentrations above 25 mM, while no inhibition
of FP1 labeling was observed. Interestingly, hSym4 and
hSym4mmp/Ala showed an inhibition pattern similar to their
corresponding parent compounds (Figure S2), indicating that
the N-terminal part of the protein is not essential for target
inhibition.
Another class of plasmodial PLCPs is the dipeptidyl amino-
peptidases (DPAPs). DPAP1 and DPAP3 are essential cysteine1550 Chemistry & Biology 19, 1546–1555, December 21, 2012 ª2012proteases during the erythrocytic cycle and are involved in
hemoglobin degradation (Klemba et al., 2004; Deu et al., 2010)
and parasite egress (Arastu-Kapur et al., 2008), respectively.
Competitive ABPP with either the probe Cy5-DCG04 or the
DPAP activity-based probe FY01 showed that neither DPAP1
(Figure 4) nor DPAP3 (Figure S3) is inhibited by Sym4. Conse-
quently, these experiments indicate that Sym4 does not act as
a general inhibitor of P. falciparum cysteine proteases but rather
preferentially inhibits food vacuole falcipains.
After these encouraging results, we turned our attention to the
determination of the inhibition potency of Sym4 in intact para-
sites. To this end, purified schizonts were treated with differentElsevier Ltd All rights reserved
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and the residual activity of PLCPs in the parasite pellets was
again labeled with Cy5-DCG-04 (Figure 4B). This assay
confirmed that Sym4 is a nanomolar inhibitor of falcipains in
intact parasites, although this time we also observed potent inhi-
bition of FP1. Quantification of the gel labeling pattern thereby
revealed a preferential inhibition of FP2/20 over FP3 or FP1
(IC50
FP2/20 = 8.5 ± 1.3 nM, IC50
FP3 = 22 ± 8 nM, IC50
FP1 = 140 ±
23 nM; Figure 4B).
To further characterize the inhibitory potency of Sym4, we
subsequently determined the kinetics of substrate turnover
inhibition, using recombinantly produced FP2 or FP3 at different
inhibitor concentrations (Figure S5). As expected, this experi-
ment confirmed that Sym4 is an irreversible inhibitor of these
two falcipains. Moreover, and in accordance with the competi-
tive ABPP experiments, FP2 turned out to be more potent than
FP3 (FP2: ki = kobs / [I] = 58,600 ± 1,400 M
1s1 versus FP3:
ki = kobs / [I] = 7,030 ± 250 M
1s1).
In order to evaluate the bioreactivity pattern of Sym4, we next
investigated if Sym4 also inhibits mammalian PLCPs or the pro-
teasome. To this end, we performed additional competitive
ABPP experiments with bone marrow-derived mouse macro-
phages in vivo. This mammalian cell line was preincubated
with 0.5 mM and 5 mM of Sym4, hSym4, Sym4mmp/Ala,
or hSym4mmp/Ala. Then, selected residual protease activities
were determined by incubating protein extracts with a broad-
band PLCP ABP (Greenbaum et al., 2002a) (Figures S4A and
S4B) or with a proteasome-specific ABP (Kolodziejek et al.,
2011) (Figures S4C and S4D). In these assays, Sym4, hSym4,
Sym4mmp/Ala, or hSym4mmp/Ala did not inhibit the protea-
some (Figures S4CandS4D). In contrast, we observed a concen-
tration-dependent inhibition of cathepsins in these experiments.
Both Sym4 and hSym4 were found to inhibit cathepsin L at
0.5 mM (Figure S4A). At the 5 mM concentration, cathepsins B,
H, S, and Z were also inhibited. As observed with the falcipains,
the Sym4 derivatives lacking the mmp group were less active.
Sym4mmp/Ala orhSym4mmp/Ala did not inhibit any cathepsins
at 0.5 mM, but did inhibit cathepsin L at 5 mM (Figure S4B). We
then tested the labeling properties of the fluorescent probes
RhSym4 and RhSym4mmp/Ala also with bone marrow-derived
mouse macrophages (Figure S4E). Interestingly, the obtained
labeling profile indicates, as expected from the competitive
ABPP experiments, that the predominant target of Sym4 in
mammalian cells is cathepsin L.
DISCUSSION
Half of the human population is threatened by malaria, and the
urge to develop novel antimalarial therapies is becoming more
and more pressing (Guiguemde et al., 2012). Compounds with
antimalarial activity are frequently reported in the literature
(Nogueira and Lopes, 2011), but further development of these
compounds into drugs is often hampered by their difficult chem-
ical synthesis (or limited availability via natural product isolation)
and/or their unknown mode of action.
The natural product symplostatin 4 (Sym4) has been identified
as another promising antimalarial compound (Conroy et al.,
2010, 2011). To investigate the mode of action of this promising
antimalarial agent, we synthesized several analogs to (1) identifyChemistry & Biology 19, 1546–155its direct molecular targets and (2) characterize the underlying
structure-activity relationships and correlate them to the antima-
larial activities.
Synthesis of Sym4 and Derivatives
We first developed a convergent synthesis to Sym4 and deriva-
tives. In order to establish a synthetic route that allows rapid
access to different Sym4 derivatives, a modular synthesis was
devised. Thus, in contrast to previous synthetic approaches,
which relied on a stepwise assembly of different amino acid
building blocks, we chose a fragment condensation strategy
to assemble the Sym4 framework. Consequently, two different
N- and C-terminal fragments were synthesized via solution
phase peptide synthesis and merged to four different Sym4
derivatives. This approach was used to synthesize not only
the natural product Sym4, but also derivatives lacking the
C-terminal mmp group. In addition, derivatives with a propargyl
group at the N terminus were generated, which enabled the
attachment of a fluorescent reporter rhodamine via a copper-
catalyzed click reaction in an additional reaction step (RhSym4
and RhSym4mmp/Ala).
Altogether, the developed synthetic route allows a rapid and
facile generation of Sym4 and derivatives, using ‘‘standard’’
peptide chemistry manipulations. However, because malaria
mostly affects people in third world countries that cannot afford
expensive medication, the cost of goods of a synthesis is always
an important issue. Although the prices for the required starting
materials (i.e., mainly amino acids and other peptide chemistry
reagents) have decreased significantly in the last few years,
the overall costs of the chemical synthesis of Sym4 derivatives,
even if established on an industrial scale, will most probably
exceed the generally accepted $2 limit. Thus, for a chemothera-
peutic utilization of Sym4, further compound optimization, in
regard not only to its bioactivities but also to the cost of
synthesis, is still required; along these lines, Sym4 derivatives
featuring a structurally less complex N-terminal fragment but
maintaining the biologically relevant C-terminal moieties might
be more appropriate drug candidates.
Falcipain Inhibition Is Responsible for the Antimalarial
Activity of Sym4
The evaluation of the biological activity of chemically synthe-
sized Sym4 confirmed that this natural product is a potent anti-
malarial compound, as was previously reported (Conroy et al.,
2010, 2011). In phenotypic assays, we subsequently showed
that Sym4 causes a distinct food vacuole defect at nanomolar
concentrations (Figure 2). These findings guided our following
target identification studies using competitive ABPP, which
demonstrated all four P. falciparum falcipains as targets of
Sym4 in intact parasites. However, we observed different inhibi-
tion potencies: Sym4most potently inhibited FP2/20, followed by
FP3 and FP1. Among the different falcipains, FP3 is the only one
for which knockout attempts have been unsuccessful, which
suggests it is the most important falcipain during P. falciparum
blood stages. FP1 and FP20 knockout strains have no apparent
phenotype, with FP1 not being essential in the erythrocytic stage
of malaria (Sijwali et al., 2004), while the FP2 knockout showed
a marked food vacuole defect (Sijwali et al., 2004; Sijwali and
Rosenthal, 2004). To the best of our knowledge, the FP2/205, December 21, 2012 ª2012 Elsevier Ltd All rights reserved 1551
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that inhibition of both FP2 homologs is lethal to parasites. With
this caveat inmind, our findings suggest that FP3 inhibitionmight
be the crucial factor for the antimalarial activity of Sym4.
Although we observed the formation of a food vacuole defect
at 0.1 mM Sym4, parasite killing (i.e., the antimalarial activity)
required 7-fold higher concentrations (EC50 = 0.7 mM). The
different concentrations required to induce parasite killing on
the one hand, and the formation of the food vacuole defect on
the other hand, might at least partly result from the falcipain inhi-
bition profile of Sym4. Although at lower concentrations Sym4
first inhibits FP2/20 and thus causes a food vacuole phenotype,
higher concentrations are required for supplementary FP3 inhibi-
tion, thereby inducing parasite killing. In any case, it is important
to note that Sym4 inhibits falcipains in intact parasites with IC50s
in the low tomedium nanomolar range, which is much lower than
the observed EC50 of 0.7 mM in the replication assay. Several
reasons might explain the discrepancy between these two
values. First, high fractional and sustained inhibition of falcipains
might be required to impair parasite replication. This has been
observed for DPAP1, where sustained inhibition of more than
90% of DPAP1 activity for several hours is required to effectively
block parasite replication (Deu et al., 2010). Therefore, the
required concentrations of Sym4 for impairing P. falciparum
replication via inhibition of falcipains needs to be much higher
than the actual IC50 value. The fact that Sym4 does not irrevers-
ibly block egress also indicates that Sym4 does not inhibit other
cysteine proteases involved in schizont rupture, such as DPAP3
(Figure S3) or human calpain-1 (Chandramohanadas et al., 2011;
Millholland et al., 2011). Second, the intramolecular Sym4
concentration and thus the ‘‘reservoir’’ of ‘‘free’’ Sym4 that is
available to target falcipains might be lower than anticipated,
thereby resulting in less efficient falcipain inhibition. Several
mechanisms might lead to such a reduced Sym4 concentration.
For example, although our studies indicate that falcipains are cell
permeable, the uptake of extracellular Sym4 into the cytosol
might be hampered or slowed down. In addition, it is reasonable
to assume that off-target binding to other proteins or cell compo-
nents reduce the amount of ‘‘free’’ Sym4; although some of
these binding events might be reversible, the reaction of Sym4
with host cathepsins such as cathepsin L (Figure 4A), for
example, is most probably irreversible, thereby persistently
reducing Sym4 levels. Finally, intracellular Sym4 might also be
metabolically or chemically instable and thus intracellular
Sym4 levels could be subject to a continuous decline. Interest-
ingly, in our replication assay parasites were treated at ring
stage, while for example FP3 is known to be expressed at
schizont stage (i.e., more than 24 hr after treatment). At this
point, Sym4 concentration may already be significantly reduced,
thereby explaining the observed bioactivity difference between
falcipain inhibition in intact parasites and the EC50 on infected
red blood cells.
Despite these drawbacks, our experiments revealed Sym4 as
one of the most potent falcipain inhibitors reported so far
(Teixeira et al., 2011). This potency is accompanied by a distinct
selectivity pattern. By performing comparative ABPP ex-
periments with a specific proteasome probe in living cells
(MVB003), we could verify that Sym4 does not inhibit the
mammalian proteasome at concentrations up to 5 mM (highest1552 Chemistry & Biology 19, 1546–1555, December 21, 2012 ª2012tested concentration; Figure S4C). However, a similar assay
testing for activity against mammalian cathepsins using
BODIPY-DCG04 (Greenbaum et al., 2002a) showed that Sym4
also reacts with mammalian cathepsins. Our assays indicated
that among the different cathepsins, Sym4 preferentially reacts
with cathepsin L. In an uninfected mammalian cell line, Sym4
inhibits a large portion of cathepsin L at a concentration of
0.5 mM and thus at a concentration comparable to the observed
antimalarial effect of Sym4. In contrast, the cathepsins B, H, S,
and Z required ten times higher concentrations (i.e., 5 mM) to
reach the same inhibition level (Figure S4A). Although the
observed ‘‘off-target’’ inhibition of cathepsin L is not desirable,
a recent report indicated that only a high fractional inhibition of
cathepsins (i.e., more than 95% inhibition) leads to a consider-
able biological effect (Me´thot et al., 2008). Nevertheless, these
findings indicate that further studies are required to evaluate
the impact of off-target cathepsin inhibition for the further
utility of Sym4 as a guiding structure for the development of
antimalarials.
Finally, as a spin-off of our studies, we observed that the syn-
thesized rhodamine analog RhSym4 strongly labels the food
vacuole falcipains in intact parasites (Figure 3). To the best of
our knowledge, this is the first activity-based probe that discrim-
inates between the food vacuole falcipains and FP1, and the first
fluorescent activity-based probe that labels FP2, 20, and 3 in
intact cells. Therefore, development of probes based on the
Sym4 scaffold might prove to be very useful tools for imaging
PLCP activity in cells.
The mmp Group Is Critical for Efficient Inhibition
of Falcipains
In order to better understand the structure-activity relationship of
Sym4, we tested different N- and C-terminal derivatives for their
antimalarial activity. We found that changes at the N-terminal
endwerewell tolerated and had only a slight effect on bioactivity.
For example, thehSym4 derivative showed a similar inhibition
pattern as Sym4 (Figures S2 and S4B). These findings indicate
that the N-terminal part of Sym4 is amenable for at least slight
modifications and not essential for target recognition. These
findings are indeed corroborated by previous synthetic studies
of Sym4 derivatives (Conroy et al., 2010, 2011).
On the other hand, replacement of the C-terminal mmp group
with an alanine (Sym4mmp/Ala) results in severe loss of antima-
larial potency. This is very interesting because the mmp group is
rarely found in natural products, and most falcipain inhibitors re-
ported so far have peptide-like structures at the C-terminal end,
similar to the Sym4mmp/Ala derivative. In parasite assays,
Sym4mmp/Ala proved to be a much weaker inhibitor of the falci-
pains than Sym4 (Figure 4), which explains its reduced antima-
larial activity (Figure 2). Furthermore, our results indicate that
the mmp group has a decisive influence on not only the potency
of falcipain inhibition, but also for other PLCPs (Figures S4A and
S4B). Although we have not further investigated the molecular
basis of the different activity patterns, we anticipate that different
factors might contribute to the observed increase of activity. For
example, the mmp groupmight occupy a distinct binding pocket
in the active site of falcipains. The resulting increase in binding
affinity and thus local concentration of Sym4 would conse-
quently favor the subsequent irreversible reaction with the activeElsevier Ltd All rights reserved
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Alternatively, the mmp group may also increase the overall
chemical reactivity of Sym4. In fact, we observed a stronger
background labeling for RhSym4 versus RhSym4mmp/Ala (Fig-
ure 3), suggesting that higher chemical reactivity may contribute
to the improved inhibition rate. On the other hand, it has been
frequently noticed that attaching fluorescent groups like rhoda-
mine or BODIPY to electrophiles like Michael systems or epox-
ides increases the off-target labeling of these ABPs when
compared to strictly biotinylated ABPs. Taken together, the
mmp group enhances the overall falcipain inhibition rate but
may also increase off-target effects. Therefore, future chemical
derivatizations of the Sym4 structure aiming at the improvement
of its inhibitory potential will have to be complemented by selec-
tivity studies.
Finally, it is important to note that falcipains have been recog-
nized as potential targets for the development of antimalarials
for quite some time, and numerous compound classes have
evolved that address these enzymes (Teixeira et al., 2011).
Among them, peptidic small molecules featuring an electrophilic
warhead such as epoxides or Michael acceptor systems have
proven to be potent inhibitors. Despite intense efforts, none of
these compounds could be developed into a drug and, there-
fore, interest in falcipain inhibitors has slightly decreased in the
last few years. Sym4 is also based on an a,b-unsaturated
Michael acceptor system that is, however, C-terminally linked
to a mmp group, resulting in a structurally novel scaffold that
has, so far, not been investigated. Indeed, our findings indicate
that this unusual combination results in much more potent
inhibitors, suggesting that further studies, for example with
N-terminally modified, less peptidic derivatives, might represent
a feasible approach to finally tackle these drug targets.SIGNIFICANCE
In summary, we have reported a total synthesis of Sym4 and
the rational synthesis of a series of analogs. Sym4 causes
a food vacuole phenotype in Plasmodium-infected RBCs
and inhibits pathogen replication with an EC50 of 0.7 mM.
We subsequently identified the falcipains as direct molec-
ular targets of Sym4, thereby explaining its potent antima-
larial properties. Finally, we elucidated the C-terminal mmp
unit as a critical component for potent inhibition of falci-
pains. Therefore, our findings not only provide the mecha-
nistic basis for the observed potent antimalarial properties
of the marine natural product symplostatin 4 (Sym4), but
theymay also serve as a valuable guide for the future rational
design of potent falcipain inhibitors. Although an assess-
ment of the drug-like properties of Sym4 has yet to be
done, we anticipate that the synthesis of Sym4-like deriva-
tives opens new possibilities to the design of tool com-
pounds to investigate and develop antimalarial chemothera-
peutics that combat this devastating disease.EXPERIMENTAL PROCEDURES
Parasite Culture, Harvesting, and Lysate Preparation
D10 P. falciparum were cultured and kept synchronous as previously
described (Arastu-Kapur et al., 2008). Trophozoite stage parasites wereChemistry & Biology 19, 1546–155harvested 36 hr postinvasions. Parasites were released and isolated from
RBCs after saponin lysis of the RBC membrane. Proteins were extracted
from parasites by treatment with PBS containing 1% NP40. The soluble
fraction was subsequently separated from the insoluble one by centrifugation
(Arastu-Kapur et al., 2008).
Phenotypic Characterization of Sym4-Treated Parasites
A synchronized culture of the parasite at ring stage (2% parasitemia) was
treated with different concentrations of Sym4, Sym4 analogs, or DMSO. After
24 hr, phenotypic effects were observed by Giemsa-stained thin blood
smears. The food vacuole defect is clearly visible as an enlargement of this
acidic organelle. This is due to the inhibition of proteases in the food vacuole
that leads to the accumulation of undigested hemoglobin.
P. falciparum Replication Assay
A total of 200 ml synchronous D10 parasites at ring stage (2% parasitemia and
0.5% hematocrit) were treated with the corresponding compounds and
cultured in 96-well plates for 75 hr until the DMSO controls reached schizont
stage. Quantification was performed by flow cytometry as previously
described (Wang et al., 2011). All fluorescence activated cell sorting measure-
ments were taken on a BD FACScan flow cytometer (Becton Dickinson). EC50
values for parasite death were obtained by fitting the parasitemia values to
a dose-response curve.
Labeling of Cysteine Protease Activity with ABPs and Competition
of Labeling by Protease Inhibitors
Cy5-DCG04, a cell-impermeable fluorescently tagged activity-based probe
was used to label the activity of DPAP1 and falcipains in lysates. To test the
potency of Sym4 and analogous compounds, parasite lysates (diluted 1:10
in acetate buffer [50 mM sodium acetate, 5 mM MgCl2, and 5 mM DTT at
pH 5.5]) were pretreated with the corresponding compounds for 30 min
followed by labeling for 1 hr with 1 mM of Cy5-DCG04. The reaction was
stopped by boiling the samples in SDS-PAGE loading buffer. Proteins were
resolved by SDS-PAGE and the different cysteine proteases were detected
using a Typhoon 9410 flat-bed fluorescence scanner (Amersham Biosciences,
GE Healthcare).
Labeling of proteins from intact parasites with RhSym4 and
RhSym4mmp/Ala was performed by incubating purified schizonts with
different concentration of RhSym4 for 1 hr in PBS followed by boiling of the
samples in loading buffer and separation of the different proteins by SDS-
PAGE. Labeled bands were detected using the Typhoon 9410 scanner.
To measure falcipain inhibition in living parasites, a culture of P. falciparum
at 20% parasitemia and 2% hematocrit was treated with different concentra-
tions of Sym4. After 1 hr of treatment, a 1 ml aliquot of culture was lysed with
0.15% saponin in PBS buffer, the parasite pellets were harvested, and residual
cysteine protease activity was detected by labeling with 1 mM of Cy5-DCG04
for 1 hr in acetate buffer containing 1%NP40. After SDS-PAGE, the labeling of
FP1, FP2/20, FP3, and DPAP1 was quantified using the ImageJ software
(Abra´moff et al., 2004) and fitted to a sigmoidal dose response curve to obtain
IC50 values.
Ki DeterminationUsing a Biochemical Activity Assay for FP2 and FP3
Inhibition values of recombinantly produced FP2 and FP3 were measured at
25C in assay buffer (200 mM sodium acetate, 10 mM DTT, 0.01% Triton-X,
3.625% glycerol, pH 6) containing 25 mM of Z-LR-AMC. Substrate turnover
was measured for 2 hr in a 96-well plate at 460 nm (lexcitation = 350 nm and
an emission cutoff filter at 435 nm) in a SpectramaxM5plate-reader (Molecular
Devices).
Accurate ki values (corresponding to kobs / [I]) for Sym4 (second order rate
constant of inhibition) were obtained by incubation of FP2 or FP3 with different
concentrations of Sym4 and by recording the decrease in activity over time.
The rates of substrate turnover relative to the DMSO controls (v/v0) were fitted
to a simple irreversible inhibitor model:
E+ I/
ki
E I (Equation 1)
v
vo
= expð kobs$½I$tÞ:5, December 21, 2012 ª2012 Elsevier Ltd All rights reserved 1553
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The synthesis and characterization of compounds 1 to 8 as well as Sym4 and
Sym4 derivatives are described in Supplemental Experimental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.chembiol.2012.09.020.
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